Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Articles|August 11, 2017
Which Came First: Fatigue or Depression?
Author(s)Steven D. Targum, MD
5 key questions to ask as part of a comprehensive differential assessment of fatigue and depression.
Advertisement
The onset of some fatigue symptoms may suggest an emerging illness and often occurs as part of a medical and/or psychiatric disorder. Here are 5 key questions to ask as part of a comprehensive differential assessment of fatigue and depression.
For the full article on which this video is based, as well as the free CME post-test, see
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
5